Clinics in Dermatology
Volume 25, Issue 6 , Pages 535-546 , November 2007

Psoriasis: epidemiology

  • Johann E. Gudjonsson, MD

      Affiliations

    • Department of Dermatology, University of Michigan School of Medicine, Box 0932, Ann Arbor, MI 48109-0932, USA
    • Department of Radiation Oncology, University of Michigan School of Medicine, Box 0932, Ann Arbor, MI 48109-0932, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 734 763 0355; fax: +1 734 763 4575.
    • ,
  • James T. Elder, MD

      Affiliations

    • Ann Arbor Veterans Affairs Hospital, Ann Arbor, MI USA

References 

  1. Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A. The annual cost of psoriasis. J Am Acad Dermatol. 1993;28:422–425
  2. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78:827–851
  3. Farber EM, Nall L. Epidemiology: natural history and genetics. In:  Roenigk HH,  Maibach HI editor. Psoriasis. New York: Dekker; 1998;p. 107–157
  4. Christophers E. Psoriasis—epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314–320
  5. Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol. 1984;10:965–968
  6. Shao CG, Zhang GW, Wang GC. Distribution of psoriasis in China: a nationwide screening. Proc Chin Acad Med Sci Peking Union Med Coll. 1987;2:59–65
  7. Lin XR. Psoriasis in China. J Dermatol. 1993;20:746–755
  8. Barisic-Drusko V, Paljan D, Kansky A, Vujasinovic S. Prevalence of psoriasis in Croatia. Acta Derm Venereol Suppl (Stockh). 1989;146:178–179
  9. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol. 1981;61:344–346
  10. Lomholt G. Psoriasis: prevalence, spontaneous course, and genetics. In: Lomholt G, editor. Published Ph.D. Thesis. Copenhagen: G.E.C. GAD, 1963.
  11. Braathen LR, Botten G, Bjerkedal T. Prevalence of psoriasis in Norway. Acta Derm Venereol Suppl (Stockh). 1989;142:5–8
  12. Kavli G, Forde OH, Arnesen E, Stenvold SE. Psoriasis: familial predisposition and environmental factors. Br Med J (Clin Res Ed). 1985;291:999–1000
  13. Kavli G, Stenvold SE, Vandbakk O. Low prevalence of psoriasis in Norwegian Lapps. Acta Derm Venereol. 1985;65:262–263
  14. Falk ES, Vandbakk O. Prevalence of psoriasis in a Norwegian Lapp population. Acta Derm Venereol Suppl (Stockh). 1993;182:6–9
  15. Convit J. Investigation of the incidence of psoriasis among Latin American Indians. In: Proceedings of the 13th Congress on Dermatology, Amsterdam. 1962;p. 196
  16. Hellgren L. Psoriasis: The prevalence in sex, age and occupational groups in total populations in Sweden; morphology, inheritance and association with other skin and rheumatic diseases. Stockholm: Almqvist & Wiksell; 1967;
  17. Rea JN, Newhouse ML, Halil T. Skin disease in Lambeth. A community study of prevalence and use of medical care. Br J Prev Soc Med. 1976;30:107–114
  18. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol. 1996;135:533–537
  19. Johnson ML, Roberts J. Skin conditions and related need for medical care among persons 1-74 years: United States. In: E.a.W. Department of Health  editors. Vital and Health Statistics, Series 11: Data from the National Health Survey no. 212, DHEW Publication No. (PHS) 79-1660. Vol. 11:Hyattsville, (MD): Government Printing Office; 1978;p. 1971–1974
  20. Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52:23–26
  21. In:  Tsuji K,  Aizawa M,  Sasazuki T editor. HLA 1991: proceedings of the Eleventh International Histocompatibility Workshop and Conference. Vol. 1:Oxford: Oxford University Press; 1992;p. 1220
  22. Gladman DD. Natural history of psoriatic arthritis. Baillieres Clin Rheumatol. 1994;8:379–394
  23. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573
  24. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County Minnesota, USA, 1982-1991. [see comments] J Rheumatol. 2000;27:1247–1250
  25. Fry L. Psoriasis. Br J Dermatol. 1988;119:445–461
  26. Buntin DM, Skinner RB, Rosenberg EW. Onset of psoriasis at age 108. J Am Acad Dermatol. 1983;9:276–277
  27. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450–456
  28. Hoede K. The problem of heredity of psoriasis. Hautarzt. 1957;8:433–438
  29. Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 1974;109:207–211
  30. Brandrup F, Holm N, Grunnet N, Henningsen K, Hansen HE. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol. 1982;62:229–236
  31. Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. J Am Acad Dermatol. 1993;29:428–434
  32. Moll JM, Wright V, O'Neill T, Silman AJ. Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973;32:181–201
  33. Traupe H, van Gurp PJ, Happle R, Boezeman J, van de Kerkhof PC. Psoriasis vulgaris, fetal growth, genomic imprinting. Am J Med Genet. 1992;42:649–654
  34. Rahman P, Gladman DD, Schentag CT, Petronis A. Excessive paternal transmission in psoriatic arthritis. Arthritis Rheum. 1999;42:1228–1231
  35. Morison IM, Reeve AE. A catalogue of imprinted genes and parent-of-origin effects in humans and animals. Hum Mol Genet. 1998;7:1599–1609
  36. Soejima H, Wagstaff J. Imprinting centers, chromatin structure, and disease. J Cell Biochem. 2005;95:226–233
  37. Christophers E, Henseler T. Psoriasis type I and type II as subtypes of nonpustular psoriasis. In:  Roenigk H,  Maibach H editor. Psoriasis. 2nd ed. New York: Marcel Dekker; 1990;p. 15–21
  38. Risch N. Linkage strategies for genetically complex traits. II. The power of affected relative pairs. Am J Hum Genet. 1990;46:229–241
  39. Elder JT, Nair RP, Guo SW, Henseler T, Christophers E, Voorhees JJ. The genetics of psoriasis. Arch Dermatol. 1994;130:216–224
  40. Andressen C, Henseler T. Inheritance of psoriasis. Analysis of 2035 family histories. Hautarzt. 1982;33:214–217
  41. Watson W, Cann HM, Farber EM, Nall ML. The genetics of psoriasis. Arch Dermatol. 1972;105:197–207
  42. Hwu WL, Yang CF, Fann CS, et al. Mapping of psoriasis to 17q terminus. J Med Genet. 2005;42:152–158
  43. Tomfohrde J, Silverman A, Barnes R, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science. 1994;264:1141–1145
  44. Karason A, Gudjonsson JE, Upmanyu R, et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet. 2003;72:125–131
  45. F. Capon, R.C. Trembath, Barker, J.N. An update on the genetics of psoriasis. Dermatol Clin, 22: 339-347, vii, 2004.
  46. Sagoo GS, Cork MJ, Patel R, Tazi-Ahnini R. Genome-wide studies of psoriasis susceptibility loci: a review. J Dermatol Sci. 2004;35:171–179
  47. Elder JT, Nair RP, Weichenthal M, et al. The MHC genes in psoriasis. Curr Genomics. 2005;6:39–43
  48. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64(Suppl 2):ii37–ii39[discussion ii40-31]
  49. Horton R, Wilming L, Rand V, et al. Gene map of the extended human MHC. Nat Rev Genet. 2004;5:889–899
  50. Russell TJ, Schultes LM, Kuban DJ. Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med. 1972;287:738–740
  51. Choonhakarn C, Romphruk A, Puapairoj C, Jirarattanapochai K, Leelayuwat C. Haplotype associations of the major histocompatibility complex with psoriasis in Northeastern Thais. Int J Dermatol. 2002;41:330–334
  52. Ozawa A, Miyahara M, Sugai J, et al. HLA class I and II alleles and susceptibility to generalized pustular psoriasis: significant associations with HLA-Cw1 and HLA-DQB1*0303. J Dermatol. 1998;25:573–581
  53. Schmitt-Egenolf M, Eiermann TH, Boehncke WH, Ständer M, Sterry W. Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: a population- and family-based study. J Invest Dermatol. 1996;106:711–714
  54. Jenisch S, Henseler T, Nair RP, et al. Linkage analysis of human leukocyte antigen (HLA) markers in familial psoriasis: strong disequilibrium effects provide evidence for a major determinant in the HLA-B/-C region. Am J Hum Genet. 1998;63:191–199
  55. Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol. 2000;143:1177–1182
  56. Barber LD, Percival L, Valiante NM, et al. The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C. J Exp Med. 1996;184:735–740
  57. Gladman DD, Cheung C, Ng CM, Wade JA. HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol. 1999;60:259–261
  58. Espinoza LR, Vasey FB, Gaylord SW, et al. Histocompatibility typing in the seronegative spondyloarthropathies: a survey. Semin Arthritis Rheum. 1982;11:375–381
  59. Yang S, Ge HS, Zhang AP, et al. Haplotype associations of the MHC with psoriasis vulgaris in Chinese Hans. Clin Exp Dermatol. 2004;29:399–405
  60. Gudjonsson JE, Karason A, Runarsdottir EH, et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients-an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol. 2006;126:740–745
  61. Walsh EC, Mather KA, Schaffner SF, et al. An integrated haplotype map of the human major histocompatibility complex. Am J Hum Genet. 2003;73:580–590
  62. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004;135:1–8
  63. Allen M, Ishida-Yamamoto A, McGrath J, et al. Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders. Lab Invest. 2001;81:969–976
  64. Jenisch S, Westphal E, Nair RP, et al. Linkage disequilibrium analysis of familial psoriasis: identification of multiple disease-associated MHC haplotypes. Tissue Antigens. 1999;53:135–146
  65. Consortium IPG. The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a 942 affected-sib-pair cohort. Am J Hum Genet. 2003;73:430–437
  66. Bowcock AM. Psoriasis genetics: the way forward. J Invest Dermatol. 2004;122:xv–xvii
  67. Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet. 1997;6:1349–1356
  68. Samuelsson L, Enlund F, Torinsson A, et al. A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach. Hum Genet. 1999;105:523–529
  69. Zheng J, Jin S, Shi R. Confirmation of PSORS psoriasis susceptibility loci in a Chinese population. Arch Dermatol Res. 2003;295:14–18
  70. Speckman RA, Wright J, Daw A, et al. Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum Genet. 2003;112:34–41
  71. Helms C, Cao L, Krueger JG, et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet. 2003;35:349–356
  72. Hüffmeier U, Traupe H, Burkhardt H, et al. Lack of evidence for genetic association to RUNX1 binding site at PSORS2 in different German psoriasis cohorts. J Invest Dermatol. 2005;124:107–110
  73. Stuart P, Nair RP, Abecasis GR, et al. Analysis of RUNX1 binding site and RAPTOR polymorphisms in psoriasis: no evidence for association despite adequate power and evidence for linkage. J Med Genet. 2006;43:12–17
  74. Hewett D, Samuelsson L, Polding J, et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics. 2002;79:305–314
  75. Zhang XJ, He PP, Wang ZX, et al. Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese Hans. J Invest Dermatol. 2002;119:1361–1366
  76. Sagoo GS, Tazi-Ahnini R, Barker JW, et al. Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol. 2004;122:1401–1405
  77. Hardas BD, Zhao X, Zhang J, Longqing X, Stoll S, Elder JT. Assignment of psoriasin to human chromosomal band 1q21: Coordinate overexpression of clustered genes in psoriasis. J Invest Dermatol. 1996;106:753–758
  78. Zhou X, Krueger JG, Kao MC, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics. 2003;13:69–78
  79. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599–603
  80. Jenisch S, Hampe J, Elder JT, et al. CARD15 mutations in patients with plaque-type psoriasis and psoriatic arthritis: lack of association. Arch Dermatol Res. 2006;297:409–411
  81. Rahman P, Bartlett S, Siannis F, et al. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet. 2003;73:677–681
  82. Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet. 2004;13 Spec No 1:R43–R55
  83. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273:1516–1517
  84. Mee JB, Cork MJ, di Giovine FS, Duff GW, Groves RW. Interleukin-1: a key inflammatory mediator in psoriasis?. Cytokine. 2006;33:72–78
  85. Rahman P, Sun S, Peddle L, et al. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum. 2006;54:2321–2325
  86. Halsall JA, Osborne JE, Pringle JH, Hutchinson PE. Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Pharmacogenet Genomics. 2005;15:349–355
  87. Butt C, Gladman D, Rahman P. PPAR-gamma gene polymorphisms and psoriatic arthritis. J Rheumatol. 2006;33:1631–1633
  88. Campalani E, Allen MH, Fairhurst D, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol. 2006;154:345–352
  89. Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006;126:453–459
  90. Kingo K, Ratsep R, Koks S, Karelson M, Silm H, Vasar E. Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. J Dermatol Sci. 2005;37:111–113
  91. Koks S, Kingo K, Vabrit K, et al. Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun. 2005;6:407–415
  92. Plant D, Young HS, Watson RE, Worthington J, Griffiths CE. The CX3CL1-CX3CR1 system and psoriasis. Exp Dermatol. 2006;15:900–903
  93. Richter-Hintz D, Their R, Steinwachs S, et al. Allelic variants of drug metabolizing enzymes as risk factors in psoriasis. J Invest Dermatol. 2003;120:765–770
  94. Tsunemi Y, Saeki H, Nakamura K, et al. Interleukin-12 p40 gene (IL12B) 3-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci. 2002;30:161–166
  95. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, Kristinsson KG, Valdimarsson H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol. 2003;149:530–534
  96. Winfield JM. Psoriasis as a sequel to acute inflammation of the tonsils: a clinical note. J Cutan Dis. 1916;34:441–443
  97. Whyte J, Baughman R, Hanover N. Acute guttate psoriasis and streptococcal infection. Arch Dermatol. 1964;89:350–356
  98. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992;128:39–42
  99. Herbst RA, Hoch O, Kapp A, Weiss J. Guttate psoriasis triggered by perianal streptococcal dermatitis in a four-year-old boy. J Am Acad Dermatol. 2000;42:885–887
  100. Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol. 2004;138:83–93
  101. Diluvio L, Vollmer S, Besgen P, Ellwart JW, Chimenti S, Prinz JC. Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol. 2006;176:7104–7111
  102. Gudjonsson JE, Elder JT. Psoriasis: etiopathogenesis. In: R.C.T. ,  Fitzgerald O editor. Psoriatic and reactive arthritis: a companion to rheumatology. 1st ed. Philadelphia: Elsevier; 2006;p. 37–47
  103. Mallon E, Young D, Bunce M, et al. HLA-Cw*0602 and HIV-associated psoriasis. Br J Dermatol. 1998;139:527–533
  104. Duvic M, Johnson TM, Rapini RP, Freese T, Brewton G, Rios A. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol. 1987;123:1622–1632
  105. Kaplan MH, Sadick NS, Wieder J, Farber BF, Neidt GW. Antipsoriatic effects of zidovudine in human immunodeficiency virus-associated psoriasis. J Am Acad Dermatol. 1989;20:76–82
  106. Obuch ML, Maurer TA, Becker B, Berger TG. Psoriasis and human immunodeficiency virus infection. J Am Acad Dermatol. 1992;27:667–673
  107. Colebunders R, Blot K, Mertens V, Dockx P. Psoriasis regression in terminal AIDS. Lancet. 1992;339:1110
  108. Vittorio Luigi De Socio G, Simonetti S, Stagni G. Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scand J Infect Dis. 2006;38:74–75
  109. Seville RH. Psoriasis and stress. Br J Dermatol. 1977;97:297–302
  110. Harvima RJ, Viinamaki H, Harvima IT, et al. Association of psychic stress with clinical severity and symptoms of psoriatic patients. Acta Derm Venereol. 1996;76:467–471
  111. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125:61–67
  112. Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin. 2005;23:681–694
  113. Rucevic I, Perl A, Barisic-Drusko V, Adam-Perl M. The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol. 2003;27(Suppl 1):41–48
  114. Schmid-Ott G, Jacobs R, Jager B, et al. Stress-induced endocrine and immunological changes in psoriasis patients and healthy controls. A preliminary study. Psychother Psychosom. 1998;67:37–42
  115. Weiss G, Shemer A, Trau H. The Koebner phenomenon: review of the literature. J Eur Acad Dermatol Venereol. 2002;16:241–248
  116. Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148:1–18
  117. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141:1527–1534
  118. McGowan JW, Pearce DJ, Chen J, Richmond D, Balkrishnan R, Feldman SR. The skinny on psoriasis and obesity. Arch Dermatol. 2005;141:1601–1602
  119. de Menezes Ettinger JE, Azaro E, de Souza CA, et al. Remission of psoriasis after open gastric bypass. Obes Surg. 2006;16:94–97
  120. Higa-Sansone G, Szomstein S, Soto F, Brasecsco O, Cohen C, Rosenthal RJ. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2004;14:1132–1134
  121. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67:768–773
  122. Wolters M. Diet and psoriasis: experimental data and clinical evidence. Br J Dermatol. 2005;153:706–714
  123. Poikolainen K, Reunala T, Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol. 1994;130:473–477
  124. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol. 1999;135:1490–1493
  125. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–1741
  126. Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol. 1985;40:199–205
  127. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982–986
  128. Warrington KJ, Kent PD, Frye RL, et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther. 2005;7:R984–R991
  129. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722–732
  130. Michaelsson G, Gerden B, Ottosson M, et al. Patients with psoriasis often have increased serum levels of IgA antibodies to gliadin. Br J Dermatol. 1993;129:667–673
  131. Michaelsson G, Gerden B, Hagforsen E, et al. Psoriasis patients with antibodies to gliadin can be improved by a gluten-free diet. Br J Dermatol. 2000;142:44–51
  132. Elder JT, Nair RP, Henseler T, et al. The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol. 2001;137:1447–1454
  133. O'Brien M, Koo J. The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol. 2006;5:426–432
  134. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-{alpha} production. J Exp Med. 2005;202:135–143
  135. Fortes C, Mastroeni S, Leffondre K, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol. 2005;141:1580–1584
  136. Michaelsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol. 2006;54:737–738
  137. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113:1664–1675
  138. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(Suppl 2):ii30–ii36
  139. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol. 2006;54:S67–S80
  140. Capon F, Di Meglio P, Szaub P, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007;122:201–206
  141. Cargill M, Schordl SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273–290
  142. Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet. 1997;6:1349–1356
  143. Tsunemi Y, Saeki H, Nakamura K, et al. Interleukin-12 p40 gene (IL12B) 3´-untranslated region polymorphism is associated with susceptiblity to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci. 2002;30:161–166
  144. Weichenthal M, Nair R, Ruether A, et al. Genetic association of IL12B and IL23R with psoriasis (abstract). J Invest Dermatol. 2007;127:S86

PII: S0738-081X(07)00151-4

doi: 10.1016/j.clindermatol.2007.08.007

Clinics in Dermatology
Volume 25, Issue 6 , Pages 535-546 , November 2007

Article Tools

* Image Usage & Resolution